Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Mycophenolate mofetil
Clonmel Healthcare Ltd
L04AA; L04AA06
Mycophenolate mofetil
250 milligram(s)
Capsule, hard
Product subject to prescription which may be renewed (B)
Selective immunosuppressants; mycophenolic acid
Not marketed
2010-10-08
1 PACKAGE LEAFLET: INFORMATION FOR THE USER MYCOPHENOLATE MOFETIL CLONMEL 250 MG, CAPSULES, HARD Mycophenolate mofetil READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Mycophenolate mofetil is and what it is used for 2. What you need to know before you take Mycophenolate mofetil 3. How to take Mycophenolate mofetil 4. Possible side effects 5. How to store Mycophenolate mofetil 6. Contents of the pack and other information 1. WHAT MYCOPHENOLATE MOFETIL IS AND WHAT IT IS USED FOR The full name of your medicine is Mycophenolate mofetil Clonmel 250 mg, capsules, hard. In this leaflet the shorter name Mycophenolate mofetil is used. This medicine contains mycophenolate mofetil. This belongs to a group of medicines called “immunosuppressants”. Mycophenolate mofetil is used to prevent your body rejecting a transplanted organ: A kidney, heart or liver. Mycophenolate mofetil should be used together with other medicines: Ciclosporin and corticosteroids. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MYCOPHENOLATE MOFETIL WARNING Mycophenolate causes birth defects and miscarriage. If you are a woman who could become pregnant, you must provide a negative pregnancy test before starting treatment and must follow the contraception advice given to you by your doctor. Your doctor will speak to you and give you written information, particularly on the effects of mycophenolate on unborn babies. Read the information carefully and follow the instructions. If you do not fully understand these instructions Read the complete document
Health Products Regulatory Authority 05 May 2022 CRN00CTSR Page 1 of 13 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Mycophenolate mofetil Clonmel 250 mg capsules hard 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 250 mg mycophenolate mofetil. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard. Hard gelatin capsule, size 1, containing white to off-white powder, with a blue opaque capsule cap and a pink opaque capsule body, printed with ‘APO’ and ‘M250’ in black ink. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Mycophenolate mofetil is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Treatment with mycophenolate mofetil should be initiated and maintained by appropriately qualified transplant specialists. Posology USE IN RENAL TRANSPLANT _Adults_ Oral mycophenolate mofetil therapy should be initiated within 72 hours following transplantation. The recommended dose in renal transplant patients is 1 g administered twice daily (2 g daily dose). _Paediatric population aged 2 to 18 years_ The recommended dose of mycophenolate mofetil is 600 mg/m2 administered orally twice daily (up to a maximum of 2 g daily). Mycophenolate mofetil should only be prescribed to patients with a body surface area of at least 1.25 m2. Patients with a body surface area of 1.25 to 1.5 m2 may be prescribed mycophenolate mofetil at a dose of 750 mg twice daily (1.5 g daily dose). Patients with a body surface area greater than 1.5 m2 may be prescribed mycophenolate mofetil at a dose of 1 g twice daily (2 g daily dose). As some adverse reactions occur with greater frequency in this age group (see section 4.8) compared with adults, temporary dose reduction or interruption may be required; these will need to take into account relevant clinical factors including severity of reaction. _Paed Read the complete document